Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho Sells 5,742 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) General Counsel Junlin Ho sold 5,742 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $36.83, for a total value of $211,477.86. Following the transaction, the general counsel now directly owns 189,295 shares in the company, valued at approximately $6,971,734.85. The trade was a 2.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Junlin Ho also recently made the following trade(s):

• On Thursday, January 16th, Junlin Ho sold 9,039 shares of Scholar Rock stock. The stock was sold at an average price of $44.20, for a total value of $399,523.80.

Scholar Rock Stock Performance

NASDAQ:SRRK traded up $1.14 during mid-day trading on Thursday, hitting $39.15. The company’s stock had a trading volume of 670,911 shares, compared to its average volume of 911,591. The business’s fifty day moving average is $41.94 and its two-hundred day moving average is $28.09. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -16.66 and a beta of 0.50. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company’s stock worth $589,316,000 after acquiring an additional 3,439,215 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Scholar Rock by 7.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company’s stock worth $401,231,000 after acquiring an additional 629,315 shares during the period. Vanguard Group Inc. raised its position in shares of Scholar Rock by 17.6% in the fourth quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock worth $205,013,000 after acquiring an additional 708,817 shares during the period. Marshall Wace LLP raised its position in shares of Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company’s stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the period. Finally, Bellevue Group AG raised its position in shares of Scholar Rock by 16.2% in the fourth quarter. Bellevue Group AG now owns 2,510,690 shares of the company’s stock worth $108,512,000 after acquiring an additional 349,487 shares during the period. Institutional investors and hedge funds own 91.08% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Scholar Rock in a research report on Wednesday, January 29th. HC Wainwright boosted their price objective on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Finally, Truist Financial boosted their price objective on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.